[Form 4] KalVista Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Edward W. Unkart, a director of KalVista Pharmaceuticals, Inc. (KALV), reported an acquisition of a stock option on 10/01/2025. The option grants the right to buy 30,000 shares of common stock at an exercise price of $12.05. The option vests over a 12‑month period beginning with a first vesting of 1/12th on November 1, 2025, then monthly thereafter, subject to continued service. The option becomes exercisable and expires on 09/30/2035, and the reporting person is shown as holding 30,000 shares beneficially following the transaction. The Form 4 was signed on behalf of the reporting person on 10/02/2025.

Positive

• Director received equity-based compensation (30,000 option grant) which can align management and shareholder interests
• Vesting is service-based with 12-month schedule beginning 11/01/2025, supporting retention

Negative

• None.

Insights

Corporate Governance Analyst

Director option grant of 30,000 shares aligns pay with long-term performance.

The filing documents a non-derivative grant: a stock option with a $12.05 exercise price and a standard service-based vesting schedule starting 11/01/2025. Such grants are commonly used to retain executives and directors by tying compensation to future share performance.

This option is exercisable through 09/30/2035, creating a long-term incentive window that links potential upside to long-term stock performance while requiring continued service to vest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Unkart Edward W

(Last) (First) (Middle)

C/O KALVISTA PHARMACEUTICALS, INC.

200 CROSSING BOULEVARD

(Street)

FRAMINGHAM MA 01702

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KalVista Pharmaceuticals, Inc. [ KALV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$12.05	10/01/2025		A		30,000		(1)	09/30/2035	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The option vests over a 12 month period: 1/12th on November 1, 2025, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.

	/s/ Benjamin L. Palleiko, Attorney-in-Fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did KalVista director Edward Unkart report on Form 4 (KALV)?

The Form 4 reports an option grant to purchase 30,000 shares at an exercise price of $12.05, with transaction date 10/01/2025.

When does the option granted to Edward Unkart begin vesting?

The option vests over 12 months starting with 1/12th on 11/01/2025, then monthly thereafter, subject to continued service.

What are the exercisability and expiration dates for the reported option?

The option list shows an exercisability/expiration date of 09/30/2035.

How many shares does Edward Unkart beneficially own after the reported transaction?

The filing shows 30,000 shares beneficially owned following the reported transaction.

Who signed the Form 4 filing for Edward Unkart and when?

The Form 4 was signed by Benjamin L. Palleiko, Attorney-in-Fact on 10/02/2025.